Siegel J, et al. - Authors assessed the clinical and histopathologic findings, frequency, and the effect on cancer therapy of bullous eruptions due to anti-PD-1/PD-L1 therapy. The medical records of patients evaluated by the onco-dermatology clinic and consultative service of Yale New Haven Hospital from 2016 to 2018 were retrospectively reviewed. In approximately 1% of patients treated with anti-PD-1/PD-L1 therapy, bullous disorders developed. Frequently interruption of immune therapy and management with systemic corticosteroids and occasionally steroid-sparing agents were resulted by this therapy.